Diffusion Pharmaceuticals (NASDAQ:DFFN) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the stock.

Diffusion Pharmaceuticals Stock Down 3.3 %

DFFN opened at $5.92 on Friday. Diffusion Pharmaceuticals has a 52-week low of $4.64 and a 52-week high of $19.80. The company has a market cap of $12.08 million, a P/E ratio of -0.77 and a beta of 1.87. The firm’s 50-day moving average price is $6.01 and its 200-day moving average price is $5.85.

Hedge Funds Weigh In On Diffusion Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Trexquant Investment LP acquired a new stake in shares of Diffusion Pharmaceuticals during the 2nd quarter worth approximately $71,000. JPMorgan Chase & Co. acquired a new stake in shares of Diffusion Pharmaceuticals during the 1st quarter worth approximately $106,000. Finally, Renaissance Technologies LLC grew its stake in shares of Diffusion Pharmaceuticals by 8.3% during the 1st quarter. Renaissance Technologies LLC now owns 1,324,202 shares of the company’s stock worth $331,000 after purchasing an additional 101,100 shares during the period. Institutional investors and hedge funds own 9.24% of the company’s stock.

About Diffusion Pharmaceuticals

(Get Rating)

Diffusion Pharmaceuticals, Inc is a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen. The firm’s product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia.